AlphAIAlphAI — Financial news for AI agents
investing.comNOV 23 min read$INSP

Inspire Medical Systems earnings beat by $0.05, revenue topped estimates

Inspire Medical Systems (NYSE: INSP) reported Q3 EPS of $0.14, beating estimates by $0.05, with revenue at $206.7M, exceeding expectations. The company forecasted FY 2026 EPS of $1.20-$1.40 and revenue of $850M-$860M. The stock is up 14.13% over 3 months but down 8.82% year-over-year.

Original reporting
investing.com
Published Nov 2, 2026, 9:49 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 2, 2026, 9:57 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$INSP
Bullish
high confidence
Mentioned
$INSP
Relevance
9/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$INSPBullishMed
01

Why it matters

Traders can update INSP’s forward estimates using the provided FY 2026 EPS and revenue ranges, and reassess whether the beat changes the probability of meeting or exceeding guidance.

02

Market read

A straightforward earnings beat with explicit FY 2026 guidance can drive immediate re-rating and near-term momentum in INSP.

03

What to watch

The article does not include margins, procedure volumes, or backlog details, which can dominate follow-through after an earnings beat.

Relevance 9/10Novelty 8/10Timing: after-hours earnings release (published 2026-11-02 21:49:19+00:00)

Background

The piece is an Investing.com earnings report for Inspire Medical Systems’ third quarter, including consensus comparisons and FY 2026 guidance.

Company-level read

Ticker impact

$INSPBullishHigh confidence
Context

Inspire Medical Systems reported Q3 EPS of $0.14, beating the $0.09 estimate, and revenue of $206.7M versus $204.31M consensus.

Expected impact

Likely upward bias as the market digests the earnings beat and aligns FY 2026 guidance with consensus.

Evidence & confidence

The article provides the company’s own quarterly results and explicit FY 2026 guidance ranges, which are direct inputs to earnings-model updates and positioning.

Market effects

Sector

Reinforces demand confidence in the medical devices space, but the article is single-name and does not provide sector-wide read-through.

Regional

Primarily US-focused impact via a NYSE-listed issuer; no cross-market macro linkage provided.

Global

Limited global relevance beyond investor sentiment for US-listed medtech earnings.

Counterpoint

What could challenge this read

Negative EPS revisions outnumber positive ones over the last 90 days, suggesting the stock may still face skepticism despite the beat.

Key entities

  • company
    Inspire Medical Systems

    NYSE-listed medical device company reporting Q3 results and issuing FY 2026 guidance ranges.

Read at source← All news

StoryInspire Medical Systems reports Q3 2026 earnings beat and raises full‑year EPS guidance

Also covered by

1 outlet

Related articles

NOV 3
$INSPMedAI 8/10

Inspire (INSP) Q3 2026 Earnings Call Transcript

Inspire (INSP) reported Q3 2026 revenue of $206.7M, down 7.9% YoY but up 3% sequentially. The company expects stable coding framework in 2027 and a new code in 2028, with strong adoption of Inspire V. Operating loss was $28.7M, and adjusted EPS was $0.14. The company is investing in patient flow optimization and expanding market reach. According to the company, they remain confident in their path to growth.

finance.yahoo.com3 min
NOV 3
$INSPMed

Inspire: Q3 Earnings Snapshot

Inspire Medical Systems (INSP) reported a Q3 loss of $24.4M, or 84 cents per share, but adjusted earnings of 14 cents per share, beating estimates. Revenue was $206.7M, also topping forecasts. The company expects full-year earnings of $1.20-$1.40 per share and revenue of $850M-$860M.

finance.yahoo.com1 min
NOV 3
$INSPMed

Inspire Medical Systems Q3 Earnings Call Highlights

Inspire Medical Systems (INSP) reported Q3 earnings, estimating coding and reimbursement challenges reduced results by $30M and may impact 2026 results by $120M. The company expects revenue growth in Q4 and low-single-digit growth in 2027, citing stable coding and investments. Inspire highlighted a new CPT code for its Inspire V device and ongoing development of Inspire VI. Management discussed clinical evidence supporting their therapy and plans to invest in patient access and education.

finance.yahoo.com2 min
NOV 2
$INSPHighAI 8/10

Inspire Medical Q3 2026 slides: reimbursement clarity ahead, growth reset

Inspire Medical Systems reported Q3 2026 revenue of $206.7M, down 7.9% YoY but up 3.0% sequentially. The company cited reimbursement challenges as the primary headwind. Shares rose 1.83% in after-hours trading. Inspire highlighted its market position and long-term growth potential, despite near-term slowdowns. The company expects full-year 2026 revenue of $850M-$860M, down from 2025 levels.

investing.com3 min
NOV 2
$INSPMedAI 8/10

Inspire Medical Systems (NYSE:INSP) beats Q3 2026 sales expectations

Inspire Medical Systems reported Q3 2026 revenue of $206.7 million, exceeding estimates by 1.1%, and adjusted EPS of $0.14, beating estimates by 54.1%. The company reconfirmed its full-year revenue guidance of $855 million but raised adjusted EPS guidance to $1.30, a 4% increase. Operating margin declined to -13.9% from 4.3% year-on-year.

finance.yahoo.com3 min
NOV 2
$INSPMedAI 8/10

Inspire Medical Systems, Inc. Announces Third Quarter 2026 Financial Results

Inspire Medical Systems, Inc. (INSP) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Inspire Medical Systems, Inc. Announces Third Quarter 2026 Financial Results • Third quarter revenue of $206.7 million • Third quarter diluted EPS of $(0.84); adjusted diluted EPS of $0.14 • Third quarter operating cash flow of $46.4 million • AMA CPT® Editorial Pane

SEC EDGAR 8-K3 min